Analysis of tumor regression directly after CPI treatment failure.


Figure 2: Overall Survival - Interim to Final.

- **Best Target Lesion Response:**
  - **Response:**
    - Complete Response (CR): All target lesions disappear.
    - Partial Response (PR): ≥ 30% reduction in the sum of all target lesion diameters.
    - Stable Disease (SD): ≤ 20% increase or ≤ 50% decrease in the sum of all target lesion diameters.
    - Progression (PD): > 20% increase or > 50% decrease in the sum of all target lesion diameters.

- **Time to Progression:**
  - Median Time to Progression: Not reached.
  - 65% of patients alive at 6 months.


treatment failure

- **Injection Site Reactions:**
  - Pain: 10% (3/30), Itching: 5% (1/30), Erythema: 10% (3/30).

- **Other Adverse Events:**
  - Diarrhea: 10% (3/30), Nausea: 5% (1/30), Anemia: 5% (1/30), Fatigue: 5% (1/30).

- **Diagnosis:**
  - Small cell lung cancer after checkpoint inhibitor treatment failure.

- **Conclusion:**
  - HS-110 in combination with nivolumab is well tolerated.

- **References:**

- **Acknowledgments:**
  - The authors are grateful for the investigators, study staff, patients and their families for the contribution to this study and help advance the treatment of non-small cell lung cancer.